Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. As of December 31, 2025, Epigral's net debt was INR 557 crores with a net debt to EBITDA ratio of 1x, indicating a comfortable debt position. The company is focused on capex projects including capacity expansion in CPVC and epichlorohydrin and wind solar hybrid power plants, progressing on schedule within budget. No explicit indication in the call regarding raising funds via equity or additional debt. Management emphasizes disciplined capital efficiency and execution to fund growth internally. Any new ca

Any current/future capex/capital investment/strategic investment?

Capex of INR 337 crores spent; ongoing capex plans progressing as per schedule. Projects to double capacity at CPVC and epichlorohydrin, and wind solar hybrid power plants on track for commissioning within announced timeline and budget. Chlorotoluene value chain plant commissioned in March 2025, expected to contribute significantly to profit from FY27 onwards. New projects’ capex plans are being finalized, with details expected to be announced in the coming months. These investments aim to enhance integrated complex, extend value chain, and drive strong growth from FY27 onward, with si

Future growth expectations in sales/revenue/volumes?

FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued demand. Q4 FY '26 volumes likely to improve with uptick in demand from mid-November and better market conditions. CPVC demand projected to grow 10-12% annually, anticipated to reach around 320,000 tonnes by FY '27 end, with long-term growth towards 500,000 tonnes by FY '30. Chlorotoluene segment expected to contribute sizable revenue from FY '27 onwards, with major orders and contracts starting Q1 FY '27. Epigral is commissioning expansions in CPVC and epichlorohydrin capacity; ini

Future growth expectations in earnings/operating earnings/profits/EPS?

Epigral is targeting consistent growth through expansion and diversification across multiple products and industries (Page 17). Q4 FY26 expected to see better volume and margin recovery after Q3 challenges (Pages 12-13). Margins expected to improve to around 21%-23% in Q4 and onwards (Page 13). Chlorotoluene value chain plant commissioned March 2025, expected to contribute sizably to profits starting FY27 (Page 4). New capacities for CPVC and epichlorohydrin doubling planned, expected to be optimally utilized within 1-2 years, supporting revenue growth (Pages 7-9). Volume growth anti

Current/ Expected Orderbook/ Pending Orders?

Chlorotoluene segment orders are currently on a quarterly basis as customers are testing and building confidence. Actual deliveries are happening on a full truckload basis, not just samples. Major volume orders and long-term contracts are expected to begin from FY '27 onwards. The company anticipates a sizable revenue contribution from the chlorotoluene plant starting Q1 FY '27. As approvals and customer contracts finalize, order visibility will improve by March. The management is cautious about making firm commitments on orderbook percentages before contracts finalize. The increasing volumes

IN US

Sale is live|00:00:00left today

Epigral LtdQ4 FY27Chemicals & Petrochemicals

Epigral Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,106P/E: 15.8Market Cap: ₹5.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→FY '27 expected to see good volume growth as FY '26 volumes were muted due to early/prolonged monsoon and subdued demand.
→Q4 FY '26 volumes likely to improve with uptick in demand from mid-November and better market conditions.
→CPVC demand projected to grow 10-12% annually, anticipated to reach around 320,000 tonnes by FY '27 end, with long-term growth towards 500,000 tonnes by FY '30.
→Chlorotoluene segment expected to contribute sizable revenue from FY '27 onwards, with major orders and contracts starting Q1 FY '27.
→Epigral is commissioning expansions in CPVC and epichlorohydrin capacity; initial lower utilization expected post-commissioning but achieving optimal utilization within 1-2 years.
→New projects and value chain extensions set to drive significant growth from FY '29 onwards.
→Overall, management anticipates consistent growth aligned with expansion, diversification, and improving market demand.

Margin guidance

Category 3

→Epigral is targeting consistent growth through expansion and diversification across multiple products and industries (Page 17).
→Q4 FY26 expected to see better volume and margin recovery after Q3 challenges (Pages 12-13).
→Margins expected to improve to around 21%-23% in Q4 and onwards (Page 13).
→Chlorotoluene value chain plant commissioned March 2025, expected to contribute sizably to profits starting FY27 (Page 4).
→New capacities for CPVC and epichlorohydrin doubling planned, expected to be optimally utilized within 1-2 years, supporting revenue growth (Pages 7-9).
→Volume growth anticipated in FY27 due to recovery in demand after subdued FY26 (Page 13).
→New projects and expanded integrated complex set to drive significant growth from FY29 onwards (Page 4).
→Management expects improvement in overall performance and profitability from FY27 onwards onward (Pages 4, 13, 17).

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any current or planned fundraising through debt or equity.
→As of December 31, 2025, Epigral's net debt was INR 557 crores with a net debt to EBITDA ratio of 1x, indicating a comfortable debt position.
→The company is focused on capex projects including capacity expansion in CPVC and epichlorohydrin and wind solar hybrid power plants, progressing on schedule within budget.
→No explicit indication in the call regarding raising funds via equity or additional debt.
→Management emphasizes disciplined capital efficiency and execution to fund growth internally.
→Any new capex plans will be finalized and announced in the coming months, but there's no mention of external fundraising for these.

Order book

→Chlorotoluene segment orders are currently on a quarterly basis as customers are testing and building confidence.
→Actual deliveries are happening on a full truckload basis, not just samples.
→Major volume orders and long-term contracts are expected to begin from FY '27 onwards.
→The company anticipates a sizable revenue contribution from the chlorotoluene plant starting Q1 FY '27.
→As approvals and customer contracts finalize, order visibility will improve by March.
→The management is cautious about making firm commitments on orderbook percentages before contracts finalize.
→The increasing volumes in chlorotoluene indicate growing acceptance, but long-term orderbook/build-up is still in progress.

Capex plans

Yes

→Capex of INR 337 crores spent; ongoing capex plans progressing as per schedule.
→Projects to double capacity at CPVC and epichlorohydrin, and wind solar hybrid power plants on track for commissioning within announced timeline and budget.
→Chlorotoluene value chain plant commissioned in March 2025, expected to contribute significantly to profit from FY27 onwards.
→New projects’ capex plans are being finalized, with details expected to be announced in the coming months.
→These investments aim to enhance integrated complex, extend value chain, and drive strong growth from FY27 onward, with significant growth expected from FY29 onward.
→Strategy targets 70% revenue contribution from derivatives and specialty business through expansion and diversification.

How does Epigral Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Epigral Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Epigral Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio